<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103714</url>
  </required_header>
  <id_info>
    <org_study_id>08-104</org_study_id>
    <nct_id>NCT00103714</nct_id>
  </id_info>
  <brief_title>Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease</brief_title>
  <official_title>A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, 28-Day Study of Denufosol Tetrasodium (INS37217) Inhalation Solution in Patients With Cystic Fibrosis Lung Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      The objectives of this study are to evaluate the safety, tolerability and preliminary
      efficacy of two dose levels of INS37217 (denufosol tetrasodium) Inhalation Solution in
      patients with cystic fibrosis (CF) lung disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2005</completion_date>
  <primary_completion_date type="Actual">August 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>respiratory function</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in standard safety parameters</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory symptoms via questionnaire</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary exacerbation</measure>
  </secondary_outcome>
  <enrollment type="Actual">72</enrollment>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>denufosol tetrasodium (INS37217)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have confirmed diagnosis of CF

          -  Have an FEV1 greater than or equal to 60% or less than or equal to 90% of predicted
             normal

          -  Have oxygen saturation greater than or equal to 90% on room air

          -  Be clinically stable with no evidence of acute upper or lower respiratory tract
             infection or current pulmonary exacerbation

          -  Be able to reproducibly perform spirometry maneuvers

        Exclusion Criteria:

          -  Have changed their physiotherapy technique or schedule within 7 days prior to
             screening

          -  Have clinically significant comorbidities

          -  Using prior and concurrent medications according to the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amy Schaberg, BSN</last_name>
    <role>Study Director</role>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2005</study_first_submitted>
  <study_first_submitted_qc>February 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2005</study_first_posted>
  <last_update_submitted>October 19, 2015</last_update_submitted>
  <last_update_submitted_qc>October 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

